Adma Biologics Inc EV/Sales

Mi az Adma Biologics Inc EV/Sales?

A EV/Sales az Adma Biologics Inc - 6.26

Mi a EV/Sales meghatározása?



Enterprise value to sales ratio compares a company’s total value to its sales.

ttm (trailing twelve months)

Enterprise value/sales is a valuation ratio that compares the company's enterprise value to its annual sales. It indicates the company's capacity to generate free cash flow. In general, the lower the ratio, the cheaper the company is.

EV/Sales is most often calculated as cash and cash equivalents subtracted from the sum of market capitalization and debt and divided by annual sales. Many analysts consider EV/sales to be a more accurate metric than Price/Sales as it considers both debt and equity holders in its calculation. One of the limitations of the calculation is that sales do not take into account a company's taxes or expenses.

EV/Sales a Health Care szektor a NASDAQ-on cégekben a Adma Biologics Inc -hoz képest

Mit csinál Adma Biologics Inc?

adma is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of primary immune deficiency disease (pidd) and certain infectious diseases. adma's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. the target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. adma’s lead product candidate, ri-002, has completed a phase iii clinical trial in patients with pidd and has met the primary endpoint. a bla for ri-002 was accepted by the fda on september 18, 2015. the company has received u.s. patent 9,107,906. for more information, please visit the company's website at www.admabiologics.com.

ev/sales -hoz hasonló cégek Adma Biologics Inc